Ultrasound Stimulation of Insulin Release from Pancreatic Beta Cells as a Potential Novel Treatment for Type 2 Diabetes.
Ultrasound Stimulation of Insulin Release from Pancreatic Beta Cells as a Potential Novel Treatment for Type 2 Diabetes.
复制标题
DOI：
10.1016/j.ultrasmedbio.2017.01.007
复制
发表时间：
2017-06
影响因子：
2.9
通讯作者：
Zderic V
中科院分区：
文献类型：
--
作者：
Suarez Castellanos I;Jeremic A;Cohen J;Zderic V
Type 2 diabetes mellitus is a complex metabolic disease that has reached epidemic proportions in the United States and around the world. This disease is characterized by loss of insulin secretion and eventually destruction of insulin-producing pancreatic beta cells. Controlling type 2 diabetes is often difficult as pharmacological management routinely requires complex therapy with multiple medications, and loses its effectiveness over time. The objective of this study was to explore the effectiveness of a novel, non-pharmacological approach that utilizes the application of ultrasound energy to augment insulin release from rat INS 832/13 beta cells. The cells were exposed to unfocused ultrasound for 5 min at peak intensity of 1 W/cm2 and frequencies of 400 kHz, 600 kHz, 800 kHz and 1 MHz. Insulin release was measured with enzyme-linked immunosorbent assay (ELISA) and cell viability was assessed via trypan blue dye exclusion test. A marked release (approximately 150 ng/106 cells, p < 0.05) of insulin was observed when beta cells were exposed to ultrasound at 400 kHz and 600 kHz as compared to their initial control values, however this release was accompanied with a substantial loss in cell viability. Ultrasound application at frequencies of 800 kHz resulted in 24 ng/106 cells of released insulin (p < 0.05) as compared to its unstimulated base level, while retaining cell viability. Insulin release from beta cells caused by application of 800 kHz ultrasound was comparable to that reported by secretagogue glucose, thus operating within physiological secretory capacity of these cells. Ultrasound has a potential to find an application as a novel and alternative method to current approaches aimed at correcting secretory deficiencies in patients with type 2 diabetes.
